A

    Alpha Teknova Inc (TKNO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.18
    +0.06 (+0.84%)

    Market Cap: $385.48M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    82%(18/22)
    Avg Surprise
    +3.49%
    Streak
    7 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-0.05
    Revenue Consensus
    $12M
    Range$12M - $12M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.03
    Range$-0.03 - $-0.03
    1 analysts
    Revenue Consensus
    $13M
    Range$13M - $13M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 5
    		$-0.06$-0.08+25.00%Beat+14.3%
    Mar 26
    Reported May 6
    		$-0.08$-0.09+11.11%Beat+11.1%
    Dec 25
    Reported Feb 26
    		$-0.09$-0.09+0.00%Beat+18.2%
    Sep 25
    Reported Nov 6
    		$-0.08$-0.09+11.11%Beat+46.7%
    Jun 25
    Reported Aug 7
    		$-0.07$-0.10+29.72%Beat+46.2%
    Mar 25
    Reported May 8
    		$-0.09$-0.11+18.18%Beat+55.0%
    Dec 24
    Reported Mar 4
    		$-0.11$-0.12+8.33%Beat+47.6%
    Sep 24
    Reported Nov 7
    		$-0.15$-0.11-36.36%Miss+42.3%
    Jun 24
    Reported Aug 13
    		$-0.13$-0.16+18.75%Beat+27.8%
    Mar 24
    Reported May 13
    		$-0.20$-0.25+20.00%Beat+35.5%
    Dec 23
    Reported Mar 11
    		$-0.21$-0.24+12.50%Beat+55.3%
    Sep 23
    Reported Nov 9
    		$-0.26$-0.27+3.70%Beat-18.2%
    Jun 23
    Reported Aug 10
    		$-0.18$-0.28+35.71%Beat+18.2%
    Mar 23
    Reported May 10
    		$-0.31$-0.28-10.71%Miss-55.0%
    Dec 22
    Reported Mar 15
    		$-0.47$-0.34-38.24%Miss-327.3%
    Sep 22
    Reported Nov 9
    		$-0.22$-0.29+24.14%Beat-120.0%
    Jun 22
    Reported Aug 10
    		$-0.22$-0.25+12.00%Beat+51.1%
    Mar 22
    Reported May 11
    		$-0.20$-0.21+4.76%Beat-566.7%
    Dec 21
    Reported Mar 15
    		$-0.11$-0.17+35.29%Beat+67.8%
    Sep 21
    Reported Nov 10
    		$-0.10$-0.12+16.67%Beat-225.0%
    Jun 21
    Reported Aug 11
    		$-0.45$-0.18-150.00%Miss-
    Mar 21
    Reported Jun 25
    		$-0.03$-0.04+25.00%Beat-
    Dec 20
    Reported Mar 30
    		$-0.34$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$0.08$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-23.16EV/EBITDA-6.23x
    Price/FCF-52.37xFCF Yield-1.91%
    Profitability
    Profit Margin-38.40%Operating Margin-23.70%
    ROE-24.20%ROIC-20.86%
    Financial Health
    Debt/Equity0.21xInterest Coverage-18.13x
    Current Ratio4.49xQuick Ratio3.48x
    Trading Statistics
    Beta0.68Avg Volume282.96K
    52-Week High$7.8452-Week Low$1.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.20
    SMA 20$6.96
    SMA 50$5.97
    SMA 200$4.16
    EMA 10$7.16
    EMA 20$6.86
    EMA 50$6.08
    EMA 200$4.81

    MACD

    Line: 0.43Signal: 0.48Hist: -0.05

    ADX

    ADX: 28.1+DI: 20.4-DI: 16.2

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down4.0
    PSAR$7.82

    Bollinger Bands

    Upper Band$8.07
    Lower Band$5.85
    %B Position3186%(Upper)
    Band Width0.60

    RSI (14-Day)

    Neutral
    60.9

    Momentum Oscillators

    Stoch %K51.2
    Stoch %D59.4
    Williams %R-53.7
    ROC (10d)-0.6%
    Momentum-0.04
    CCI (20d)38.2
    MFI (14d)64.8

    Volatility Measures

    ATR (14d)$0.46(6.4%)
    StdDev (20d)0.55
    Hist Vol75.2%(High)

    Volume Flow

    VWAP$7.17
    OBV-8.5M
    AD Line1.1M
    CMF (20d)0.043

    Volume Metrics

    Avg Vol (20d)290.7K
    Vol Ratio0.4x(Low)
    VWMA (20d)$7.06

    Pivot Points

    R3$7.65
    R2$7.50
    R1$7.31
    Pivot Point$7.16
    S1$6.97
    S2$6.82
    S3$6.63

    Advanced Oscillators

    TSI31.18
    Ultimate Osc59.9
    KST320.29

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$12.19M$11.08M$9.98M$10.45M$10.29M$9.79M$9.27M$9.58M$9.61M$9.29M$7.87M$8.17M
    Cost of Revenue$7.30M$7.29M$6.74M$7.25M$6.30M$6.79M$7.14M$9.49M$6.81M$7.08M$6.53M$6.70M
    Gross Profit$4.88M$3.78M$3.24M$3.21M$3.98M$3.01M$2.13M$90,000$2.80M$2.21M$1.33M$1.47M
    Operating Expenses$7.78M$8.08M$7.85M$7.22M$7.37M$7.97M$7.76M$7.52M$7.90M$10.20M$12.19M$10.23M
    R&D$554,000$609,000$522,000$542,000$581,000$552,000$594,000$627,000$678,000$860,000$1.31M$1.40M
    SG&A$4.81M$5.06M$5.25M$4.65M$4.93M$5.49M$5.32M$4.97M$5.48M$7.38M$6.02M$6.14M
    Operating Income$-2,890,000$-4,298,000$-4,609,000$-4,017,000$-3,386,000$-4,964,000$-5,628,000$-7,432,000$-5,100,000$-7,986,000$-10,858,000$-8,762,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$252,000$219,000$211,000$190,000$165,000$144,000$129,000$141,000$272,000$145,000$-173,000$1.61M
    Income Before Tax$-3,140,000$-4,508,000$-4,820,000$-4,207,000$-3,551,000$-4,623,000$-5,757,000$-7,573,000$-5,372,000$-8,131,000$-10,960,000$-10,144,000
    Income Tax Expense$30,000$47,000$-62,000$79,000$19,000$22,000$-38,000$-8,000$-8,000$-34,000$-304,000$9,000
    Net Income$-3,170,000$-4,555,000$-4,758,000$-4,286,000$-3,570,000$-4,645,000$-5,719,000$-7,565,000$-5,364,000$-8,097,000$-10,656,000$-10,153,000
    EBITDA$-1,305,000$-2,762,000$-3,087,000$-2,535,000$-1,924,000$-2,997,000$-4,224,000$-5,658,000$-3,370,000$-6,266,000$-9,439,000$-6,702,000
    EBIT$-2,888,000$-4,298,000$-4,609,000$-4,017,000$-3,386,000$-4,479,000$-5,628,000$-7,432,000$-5,100,000$-7,986,000$-11,133,000$-8,529,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TKNO

    News

    Alpha Teknova at Micro-Cap Virtual Conference: clinical growth in focus

    Alpha Teknova recently presented at the Micro-Cap Virtual Conference, highlighting significant growth in its clinical products division and improved financial performance. The company reported record Q2 2025 revenue of $12.2 million and raised its full-year guidance, with adjusted EBITDA expected to turn positive in 2027. Alpha Teknova emphasized its operational efficiency, capacity for substantial revenue growth within its current infrastructure, and the strategic importance of its Clinical Solutions business, which is serving an increasing number of therapies in clinical trials.

    Investing.com•8/19/26•
    Bullish

    BTIG upgrades Alpha Teknova stock rating on improving fundamentals

    BTIG has upgraded Alpha Teknova (NASDAQ: TKNO) from Neutral to Buy, setting an $8.00 price target. This upgrade follows strong Q2 2026 results that surpassed revenue and earnings expectations, leading to raised revenue guidance for the year. The company is benefiting from improving business fundamentals, strong biotech funding, and new commercial initiatives, despite currently being unprofitable.

    Investing.com•8/11/26•
    Bullish

    TKNO Looks 52.0% Overvalued on GF Value™

    Alpha Teknova Inc (NASDAQ: TKNO) has been upgraded to a Buy rating by BTIG with an $8 price target, following a strong Q2 performance and improved funding in the life sciences sector. Despite this, GuruFocus's GF Value™ metric suggests TKNO is approximately 52.0% overvalued, with a high Price-to-Sales ratio. The company's GF Score™ of 63 indicates moderate financial health, highlighting strong growth and financial strength but weak profitability and valuation.

    GuruFocus•8/11/26•
    Neutral

    BTIG upgrades Alpha Teknova stock rating on improving fundamentals

    BTIG has upgraded Alpha Teknova Inc. (NASDAQ:TKNO) from Neutral to Buy, setting a price target of $8.00, following strong second-quarter 2026 results that exceeded revenue and earnings expectations. The company also raised its 2026 revenue guidance due to improved business fundamentals and a better funding environment in life sciences. Despite a significant stock surge and being considered overvalued, BTIG sees further upside from biotech funding, new product launches like Build-Tek, and expanding commercial investments.

    Investing.com•8/11/26•
    Bullish

    Alpha Teknova, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TKNO) 2026-08-09

    Alpha Teknova, Inc. (TKNO) released its Q2 2026 earnings call presentation on August 9, 2026. The company reported an EPS of -$0.05, which beat estimates by $0.02, and revenue of $12.19M, beating expectations by $1.28M and showing an 18.45% year-over-year increase. The presentation is related to their latest financial results.

    Seeking Alpha•8/9/26•
    Somewhat-Bullish

    Frequently Asked Questions About TKNO

    Does TKNO pay dividends?
    Alpha Teknova Inc (TKNO) does not currently pay a regular dividend.
    What is TKNO's market cap?
    Alpha Teknova Inc (TKNO) has a market capitalization of $385.48M with a current stock price of $7.18.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In